Anwer Habib,1 Hiroyoshi Mori,2 Kazuyuki Yahagi,2 *Aloke V. Finn2,3 1. Parkview Heart Institute, Fort Wayne, Indiana, USA 2. CVPath Institute Inc., Gaithersburg, Maryland, USA 3. University of Maryland School of Medicine, Baltimore, Maryland, USA *Correspondence to email@example.com Disclosure: The authors have declared no conflicts of interest. Received: 02.06.16 Accepted: 28.10.16Read More
Post Tagged with: "mammalian target of rapamycin (mTOR) inhibitors"
Editor’s Pick: Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality
Targeted therapies (vascular endothelial growth factor/vascualar endothelial growth factor receptor targeting agents and/or mammalian target of rapamycin inhibitors) for the treatment of metastatic renal cell carcinoma have changed the treatment landscape of patients suffering from end-stage renal disease requiring dialysis. Data about the pharmacokinetics of these drugs in renal failureRead More